Sign in to fuzzto save your conversations, follow your research and come back anytime.
Rainbow Childrens Medicare
SectorHealthcare
Rainbow Children's Medicare Limited is a leading chain of multi-specialty pediatric, obstetrics, and gynecology hospitals in India. Originally incorporated in 1998, it operates 16 hospitals and three clinics across six cities, with a total bed capacity of 1,655. The company specializes in pediatric services, including newborn and pediatric intensive care, multi-specialty services, and quaternary care, as well as obstetrics and gynecology services. Founded by Dr. Ramesh Kancharla, Rainbow follows a full-time, exclusive doctor-led model of healthcare delivery. The company expanded its services over the years, establishing hospitals in various cities and introducing new specialties. In 2022, Rainbow completed an Initial Public Offering and its shares were listed on the National Stock Exchange of India Limited and BSE Limited. The company also offers post-graduate DNB and fellowship programs in pediatrics.
In the news
5 Inflation-Resistant Stocks to Watch Amid Rising Retail Inflation
Rainbow Children's Medicare Q1 profit up 13% to ₹60.57 cr, Anand Rathi targets ₹1750
Rainbow Childrens Medicare Gets ESG Score of 61 from CRISIL
Prabhudas Lilladher maintains Rainbow Children's Medicare buy rating
Prabhudas Lilladher sets Engineers India target at ₹271 amid T&D sector growth
Anand Rathi recommends Rainbow Children's Medicare buy at ₹1600 target
Multiple Brokers Recommend Rainbow Children's Medicare Buy
Rainbow Children's Opens 90-Bed Hospital in Bengaluru
The Quarter story
The two most recent quarterly results, compared side-by-side.
Rainbow Childrens Medicare expands its hospital network and patient volume, but rising costs and debt are squeezing profit margins.
Revenue grew from ₹3,529.3 Cr to ₹4,699.9 Cr from Q1 FY26 to Q1 FY27 — consistent top-line expansion
EBITDA margin contracted from 29.4% to 28.6% from Q1 FY26 to Q1 FY27 — cost pressure on operations
OP consultations rose from 3,29,331 to 4,10,590 from Q1 FY26 to Q1 FY27 — strong outpatient demand
PAT margin fell from 15.2% to 13.3% from Q1 FY26 to Q1 FY27 — margin compression
Hospital count expanded from 20 to 24 from Q1 FY26 to Q1 FY27 — wider geographic reach
Material costs rose from ₹475.0 Cr to ₹645.4 Cr from Q1 FY26 to Q1 FY27 — weighing on gross margins
ARPOB increased from ₹63,323 to ₹67,256 from Q1 FY26 to Q1 FY27 — stronger revenue per bed
Finance costs increased from ₹180.8 Cr to ₹212.1 Cr from Q1 FY26 to Q1 FY27 — higher debt servicing
MF and AIF stake climbed from 13.4% to 19.9% from Q1 FY26 to Q1 FY27 — growing institutional confidence
FPI and NRI stake dropped from 23.7% to 16.0% from Q1 FY26 to Q1 FY27 — foreign investor exit
Company insights, generated from the most recent coverage.
Classic institutional distribution signature: volume spiked to 4.33 lakh shares on Sep 25 (3-month high) at ₹1,374, then 3.64 lakh on Sep 30 and 2.19 lakh on Oct 1 — high-volume down days mean big holders are exiting into weakness.
Every key support has broken in sequence — ₹1,450, ₹1,400, ₹1,350 and now ₹1,246 — each breakdown triggering fresh stop-loss selling. Next support is the psychological ₹1,200, with ₹1,145 (August lows) the critical line.
Down 1.84% to ₹1,246 on Oct 6, extending a 9.2% weekly and 13.9% monthly slide — no negative news or earnings miss, this is pure post-rally profit booking from the ₹1,610 August peak.